Total Orthobio market bouncing back and coming through 2022 smelling like a rose for the 2nd year in a row.
Among the many topics covered in detail in our comprehensive Q422/FY22 OrthoBio Recap* are:
- Complete Q422 Trauma Market Overview and Highlights
- SmartTRAK's Expert Market Analysis and Insights
- All Company News, Revenues, Data, Charts and Shares
- US Bone Replacement
- Good Momentum as Spine Rebounds and Products Launch
- US Cartilage Replacement
- Procedure Volumes Stabilizing
- US Soft Tissue Replacement
- Winter Months More Like a Sunny Day Rose Parade
- US Meniscus Replacement
- Growth Dampened by a Non-Blooming Group of Small Players
In addition to the previously mentioned market growth drivers, and as SmartTRAK highlighted in its latest trends article, “What Lies Ahead for Orthobiologics in 2023 and Beyond”,* other contributing factors of growth in 2022 and indicators of future growth in the US Orthobio market, included a tremendous level of M&As, strategic alliances and investments in new technologies. Overall, the US Orthobio market performed above expectations and ...
Read the entire Q422 Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares.*
*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.